Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Head & Neck 1Breast 1

Conditions

Peritoneal Neoplasms 1Ovarian Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1

Interventions

Letrozole 34Fulvestrant 31Specimen Handling 29ribociclib 22pembrolizumab 22Paclitaxel 21Magnetic Resonance Spectroscopy 20palbociclib 19Trastuzumab 19Anastrozole 19Carboplatin 18Capecitabine 18exemestane 17abemaciclib 16Biopsy 16Tamoxifen 15pertuzumab 14trastuzumab deruxtecan 12Cyclophosphamide 10Taxes 9Radiotherapy 8Goserelin 8Docetaxel 8giredestrant 7Standard of Care 7130-nm albumin-bound paclitaxel 7inavolisib 6eribulin 6elacestrant 6atezolizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Electrocardiography × Breast × 30 days × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡